Jim Barrett, a partner in Goodwin’s Private Equity group, is a business and securities lawyer who represents life sciences and other technology companies as well as venture capital and private equity funds. He regularly counsels boards of directors and general partners on corporate governance matters and guides their businesses through all stages of development. Accordingly, Mr. Barrett concentrates on investment transactions, mergers and acquisitions, securities law and general corporate representation. His corporate work has been recognized by Best Lawyers in America.

Mr. Barrett serves as Co-Chair of Goodwin’s Pro Bono Committee.

Areas of Practice
Domaines D’Expertise





Mr. Barrett’s work has included representing and/or advising:

  • The sale of Innovative Food Processors, Inc., an Ampersand Capital Partners portfolio company, to Balchem Corporation.
  • The sale of Dynex Technologies, Inc., an Ampersand Capital Partners portfolio company, to Telegraph Hill Partners.
  • Ampersand Capital Partners and its portfolio company Magellan Biosciences, Inc. (Magellan) in the sale of Magellan for a purchase price of $66 million to Meridian Bioscience, Inc., a fully integrated life science company that develops, manufactures, markets and distributes a broad range of diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies.
  • Ampersand Capital Partners and 1315 Capital in their acquisition of Genoptix, Inc., a provider of comprehensive testing solutions in hematology and solid tumor molecular profiling, from Novartis Pharmaceuticals Corporation.
  • The sale of Agilux Laboratories, Inc., an Ampersand Capital Partners portfolio company, to Charles River Laboratories International, Inc.
  • Ampersand Capital Partners in its acquisition of a majority stake in Corpus Medical, a provider of consulting and manufacturing services for development and commercialization of interventional medical devices. 
  • Florida Biologix in its merger with Brammer Biopharmaceuticals LLC, forming Brammer Bio, LLC, a cell and gene therapy biologics contract development and manufacturing organization.
  • Avista Pharma in its acquisition of the GMP contract manufacturing, development and animal health services business of Scynexis, Inc. (NASDAQ: SCYX).
  • Nitinol Devices and Components, Inc. (“NDC”) in its acquisition of Interface Catheter Solutions (“Interface”). NDC is the largest contract manufacturer of nitinol-based medical devices and Interface is a pioneer is medical balloon technology and the leading contract manufacturer of balloon catheter systems. Following the acquisition, NDC and Interface created Confluent Medical Technologies, a leading contract manufacturer of specialized medical devices.
  • Ampersand Capital Partners in its acquisition of Protein Technologies, a maker of peptide synthesizers and reagents.*
  • Accuratus Lab Services, an Ampersand Capital Partners portfolio company, in its acquisition of the chemistry, manufacturing and control testing services business of Array BioPharma.*
  • ChanTest Corporation, a leading private equity backed provider of specialized laboratory testing services for drug development, in its acquisition by Charles River Laboratories.*
  • Charles River Ventures in its Series A financing of a technology startup company.*
  • Ampersand Capital Partners in its minority investment in CutisPharma, an industry leader in prescription compounding pharmaceuticals.*
  • NutraMed, an Ampersand Capital Partners portfolio company, in its acquisition of Nutritional Laboratories International, Inc.*
  • ViraCor-IBT Laboratories, Inc., a premier specialty diagnostics laboratory, as general counsel, in several bolt‑on acquisitions, and in its acquisition by Eurofins Scientific for a purchase price of approximately $255 million.*
  • CRI Lifetree, a clinical research service provider, in its acquisition by clinical research organization PRA Health Sciences, a KKR portfolio company.*
  • GnuBIO Inc., a developer of fully integrated droplet-based DNA sequencing technology, as general counsel and in its acquisition by Bio-Rad Laboratories, Inc. in a merger transaction including milestone-based contingent payments.*
  • Ampersand Capital Partners in the sale of CoreLab Partners, Inc. and take-private of Bioclinica, Inc., both global clinical trial solutions businesses.*
  • Stemline Therapeutics, Inc. in its initial public offering.*
  • Modified Polymer Components, Inc. in its acquisition of Biomedical Structures, LLC.*
  • Ampersand Capital Partners in the acquisition of clinical toxicology laboratories.*
  • Sanofi-Genzyme BioVentures in its Series A financing of 4s3 Bioscience, Inc.*
  • K-TEK Corp. in its sale to ABB, the global power and automation technology group.*
  • Ampersand Capital Partners in its investments in Blue Sky Biotech, a contract research organization; Modified Polymer Components, a manufacturer of polymer components for medical device OEMs; and Accuratus Lab Services, an antimicrobial testing services business.*
  • Magellan Biosciences in the sale of its microbiology testing products division, TREK Diagnostic Systems, to Thermo Fischer Scientific.*
  • Ampersand Capital Partners in the take private of Rand Worldwide, Inc., and Rand Worldwide, Inc. in its subsequent alternative public offering (“APO”) through a reverse merger.*
  • IBT Laboratories in its merger with ViraCor Laboratories, forming ViraCor-IBT Laboratories, a leading specialty diagnostics testing lab.*
  • A syndicate of investors, including MPM Capital and Oxford Bioscience Partners, in their investment in Radius Health.*
  • Ampersand Capital Partners and SV Life Sciences in the acquisition of a controlling interest in CRI Worldwide, a leading provider of clinical research services to the pharmaceutical industry.*
  • MPM Capital and New Enterprise Associates in their investment in Rhythm, a biotechnology company developing peptide therapeutics for metabolic diseases.*
  • Ampersand Capital Partners in the leveraged buyout of K TEK Corp., a leading global manufacturer of state-of-the-art level instrumentation for liquid and bulk solids detection.*
  • Protient, Inc. in its sale to a major multi-national corporation.*
  • MPM Capital in the acquisition by Novartis AG of a majority stake in Idenix for $255 million, plus contingent payments, as well as in Idenix's IPO and follow-on offering.*
  • The APO of PharmAthene through its sale to Healthcare Acquisition Corp., in which Mr. Barrett represented Bear Stearns Health Innoventures, HealthCare Ventures and MPM Capital as the major stockholders of PharmAthene. Mr. Barrett had previously represented these investors in a $50 million financing of PharmAthene.*
  • The $350 million sale of TriPath Imaging (TPTH), an Ampersand Ventures portfolio company, to Becton, Dickinson and Company (BDX).*
  • The Series A Financing for Syndax Pharmaceuticals Inc., a company developing novel oncology products through mechanistically driven combination regimens, in which Mr. Barrett represented MPM Capital and Pappas Ventures.*
  • The Series A Financing for Claros Diagnostics, a company developing a proprietary microfluidics device to improve diagnostics in prostate cancer and other urology disorders, in which Mr. Barrett represented Oxford Bioscience Partners.*
  • The Series A financing for Cequent Pharmaceuticals, a company developing new clinically compatible therapies based on RNA interference, in which Mr. Barrett represented Ampersand Ventures.*
  • The Series C Financing for Elixir Pharmaceuticals, a company developing therapeutics to treat age-related diseases, in which Mr. Barrett represented MPM Capital.*
  • MPM Capital in its investment in Xanodyne Pharmaceuticals, a pain and women's health company, and Xanodyne's simultaneous acquisition of assets from aaiPharma for $209 million.*
  • The acquisition of Trek Diagnostic Systems and simultaneous Series A Financing of Magellan Biosciences, a clinical diagnostics company whose lead investors are Ampersand Ventures and Abingworth Management.*
  • MPM Capital in the sale of its interest in Idea AG to Celtic Pharmaceutical Holdings L.P.*
  • Oxford Bioscience Partners in the $20 million investment in and reorganization of Alantos Pharmaceuticals AG as a Delaware corporation.*
  • Cerimon Pharmaceuticals in its $70 million Series A Preferred Stock financing.*
  • Ampersand Capital Partners and SV Life Sciences in their investment in M2 Worldwide Corporation (Medifacts), a Maryland-based provider of cardiac monitoring and other clinical trial services.*
  • Open Ratings, Inc., a venture-backed on-line supply chain management company, in its acquisition by Dun & Bradstreet, Inc.*
  • Ampersand Capital Partners in its buyout of Princeton Radiology Pharmaceutical Research, a Princeton, New Jersey based provider of radiological services for use in clinical and other environments.*
  • Transport Pharmaceuticals in its conversion to a corporation and $27 million initial round of financing.*
  • Magellan Biosciences, a clinical diagnostics company, in its acquisition of TekCel, Inc.*

Mr. Barrett also has significant corporate counsel experience:*

  • Accuratus Lab Services
  • Akili Interactive Labs, Inc.
  • Albert Einstein College of Medicine of Yeshiva University
  • Ampersand Capital Partners 
  • Avista Pharma Solutions
  • BioInnovation Capital  
  • Boston Heart Diagnostics Corporation
  • Brammer Bio, LLC
  • ChanTest Corporation
  • Confluent Medical Technologies, Inc.
  • Corpus Medical, Inc.
  • CRILifetree
  • Dynex Technologies, Inc.
  • Gelesis, Inc.
  • Genoptix
  • GnuBIO Inc.
  • LabCentral Inc.
  • Magellan Biosciences, Inc.
  • Modified Polymer Components, Inc.
  • Montefiore Medical Center
  • MPM Capital
  • PureTech
  • Rand Worldwide, Inc.
  • Solasia Pharma K.K.
  • Tal Medical, Inc.
  • ViraCor-IBT Laboratories, Inc. 

*Denotes experience prior to joining Goodwin.

Professional Experience

Prior to joining Goodwin in 2015, Mr. Barrett was a partner at Locke Lord in Boston, where he served as co-chair of its private equity/venture capital group.

In The News









J.D., 1987
University of Pennsylvania Law School
B.A., 1983
University of Pennsylvania
(magna cum laude)



Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique